Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study
- 13 April 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (1) , 93-102
Abstract
Objectives: We aimed to investigate the risk of first primary cancer in patients with RA treated with janus kinase inhibitors (JAKi) compared with those who received biologic DMARDs (bDMARDs) in a real-world setting. Methods: We performed an observational cohort study using the nationwide registers in Denmark. Patients with RA aged 18+ years, without a previous cancer diagnosis, and who initiated treatment with JAKi or bDMARDs from 1 January 2017 to 31 December 2020 were followed for any cancer (except non-melanoma skin cancer). We applied inverse probability of treatment weighting (IPTW) to account for covariate differences between treatment groups. IPTW-generated weights were used with cause-specific Cox (CSC) models to calculate hazard ratios (HRs) for cancer incidence in JAKi-treated compared with bDMARD-treated patients with RA. Results: We identified 875 and 4247 RA patients treated with JAKi and bDMARDs, respectively. The JAKi group contributed 1315 person years (PYRS) and 19 cancers, the bDMARD group contributed 8597 PYRS and 111 cancers, with corresponding crude incidence rates per 1000 PYRS of 14.4 and 12.9. Comparing the two groups using weighted CSC models, a HR of 1.41 (95% CI 0.76, 2.37, 95% CIs) was seen for JAKi- vs bDMARD-treated patients with RA. Conclusion: JAKi treatment in real-world patients with RA was not associated with a statistically significant increased risk of first primary cancer compared with those who received bDMARDs. However, several numerically increased risk estimates were detected, and a clinically important excess risk of cancer among JAKi recipients cannot be dismissed.Keywords
Funding Information
- Danish Rheumatism Association
- Danish Cancer Society
This publication has 36 references indexed in Scilit:
- Cancer awareness and socio-economic position: results from a population-based study in DenmarkBMC Cancer, 2014
- The Danish Civil Registration System as a tool in epidemiologyEuropean Journal of Epidemiology, 2014
- Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO RegistryAnnals of the Rheumatic Diseases, 2013
- Danish education registersScandinavian Journal of Public Health, 2011
- The Danish Cancer RegistryScandinavian Journal of Public Health, 2011
- Validity and underrecording of diagnosis of COPD in the Danish National Patient RegistryRespiratory Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis & Rheumatism, 2006
- Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in DenmarkEuropean Journal Of Cancer Prevention, 2002